請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6522
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 田蕙芬 | |
dc.contributor.author | Yin-Kai Chen | en |
dc.contributor.author | 陳尹愷 | zh_TW |
dc.date.accessioned | 2021-05-17T09:14:22Z | - |
dc.date.available | 2015-09-19 | |
dc.date.available | 2021-05-17T09:14:22Z | - |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-16 | |
dc.identifier.citation | 1. Kidd T, Brose K, Mitchell KJ, Fetter RD, Tessier-Lavigne M, Goodman CS, et al. Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell. 1998;92(2):205-15. Epub 1998/02/11.
2. Wong K, Park HT, Wu JY, Rao Y. Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Current opinion in genetics & development. 2002;12(5):583-91. Epub 2002/08/30. 3. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature. 2005;436(7048):193-200. Epub 2005/07/15. 4. Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nature medicine. 2008;14(4):448-53. Epub 2008/03/18. 5. Bedell VM, Yeo SY, Park KW, Chung J, Seth P, Shivalingappa V, et al. roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci U S A. 2005;102(18):6373-8. Epub 2005/04/26. 6. Marlow R, Binnewies M, Sorensen LK, Monica SD, Strickland P, Forsberg EC, et al. Vascular Robo4 restricts proangiogenic VEGF signaling in breast. Proc Natl Acad Sci U S A. 2010;107(23):10520-5. Epub 2010/05/26. 7. Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics. 2002;79(4):547-52. 8. Gorn M, Anige M, Burkholder I, Muller B, Scheffler A, Edler L, et al. Serum levels of Magic Roundabout protein in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2005;49(1):71-6. Epub 2005/06/14. 9. Shackney SE, Ford SS, Wittig AB. Kinetic-microarchitectural correlations in the bone marrow of the mouse. Cell and tissue kinetics. 1975;8(6):505-16. Epub 1975/11/01. 10. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood cells. 1978;4(1-2):7-25. Epub 1978/01/01. 11. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149-61. Epub 2004/07/21. 12. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nature medicine. 2006;12(6):657-64. Epub 2006/05/23. 13. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109-21. Epub 2005/07/02. 14. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nature medicine. 2004;10(1):64-71. Epub 2004/01/02. 15. Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91(12):4523-30. Epub 1998/06/17. 16. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977-88. Epub 2006/12/19. 17. Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. The Journal of experimental medicine. 2008;205(4):777-83. Epub 2008/04/02. 18. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104(2):550-7. Epub 2004/04/01. 19. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109(2):786-91. Epub 2006/08/05. 20. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95(1):309-13. Epub 1999/12/23. 21. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637-44. Epub 2001/02/07. 22. Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2002;16(7):1302-10. Epub 2002/07/03. 23. Shih TT, Hou HA, Liu CY, Chen BB, Tang JL, Chen HY, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood. 2009;113(14):3161-7. Epub 2008/11/08. 24. Hou HA, Chou WC, Lin LI, Tang JL, Tseng MH, Huang CF, et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leukemia research. 2008;32(6):904-12. Epub 2007/10/02. 25. Litwin C, Leong KG, Zapf R, Sutherland H, Naiman SC, Karsan A. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. American journal of hematology. 2002;70(1):22-30. Epub 2002/05/08. 26. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends in immunology. 2007;28(7):299-307. Epub 2007/06/15. 27. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861-5. Epub 2008/12/20. 28. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114(6):1150-7. Epub 2009/04/30. 29. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(9):2519-26. Epub 2008/05/03. 30. Forsberg EC, Prohaska SS, Katzman S, Heffner GC, Stuart JM, Weissman IL. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS genetics. 2005;1(3):e28. Epub 2005/09/10. 31. Shibata F, Goto-Koshino Y, Morikawa Y, Komori T, Ito M, Fukuchi Y, et al. Roundabout 4 is expressed on hematopoietic stem cells and potentially involved in the niche-mediated regulation of the side population phenotype. Stem Cells. 2009;27(1):183-90. Epub 2008/10/18. 32. Smith-Berdan S, Nguyen A, Hassanein D, Zimmer M, Ugarte F, Ciriza J, et al. Robo4 cooperates with CXCR4 to specify hematopoietic stem cell localization to bone marrow niches. Cell stem cell. 2011;8(1):72-83. Epub 2011/01/08. 33. Forsberg EC, Passegue E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM, et al. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PloS one. 2010;5(1):e8785. Epub 2010/01/26. 34. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-6. Epub 2009/04/14. 35. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(28):4767-73. Epub 2009/09/02. 36. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17):3917-24. Epub 2012/02/07. 37. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65. Epub 2010/04/14. 38. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-83. Epub 2000/12/09. 39. Damm F, Heuser M, Morgan M, Wagner K, Gorlich K, Grosshennig A, et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood. 2011;117(17):4561-8. Epub 2011/03/05. 40. Scholzel C, Lowenberg B. Stimulation of proliferation and differentiation of acute myeloid leukemia cells on a bone marrow stroma in culture. Experimental hematology. 1985;13(7):664-9. Epub 1985/08/01. 41. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003;100 Suppl 1:11842-9. Epub 2003/09/25. 42. Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer genetics and cytogenetics. 1995;84(1):60-8. Epub 1995/10/01. 43. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer research. 2006;66(6):3310-6. Epub 2006/03/17. 44. Chen CY, Lin LI, Tang JL, Tsay W, Chang HH, Yeh YC, et al. Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2006;20(6):1155-8. Epub 2006/04/07. 45. Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115(25):5222-31. Epub 2010/04/07. 46. Hou HA, Chou WC, Lin LI, Chen CY, Tang JL, Tseng MH, et al. Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008;22(5):1075-8. Epub 2007/11/02. 47. Shiah HS, Kuo YY, Tang JL, Huang SY, Yao M, Tsay W, et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2002;16(2):196-202. Epub 2002/02/13. 48. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(4):1372-9. Epub 2005/03/05. 49. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. The New England journal of medicine. 2005;352(3):254-66. Epub 2005/01/22. 50. Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114(26):5352-61. Epub 2009/10/08. 51. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. The New England journal of medicine. 2010;363(25):2424-33. Epub 2010/11/12. 52. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086-94. Epub 2010/08/10. 53. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803-10. Epub 2011/08/11. 54. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010;115(14):2749-54. Epub 2010/01/26. 55. Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2011;25(2):246-53. Epub 2010/11/17. 56. Yeh JR, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development. 2008;135(2):401-10. Epub 2007/12/25. 57. Kallianpur AR, Jordan JE, Brandt SJ. The SCL/TAL-1 gene is expressed in progenitors of both the hematopoietic and vascular systems during embryogenesis. Blood. 1994;83(5):1200-8. Epub 1994/03/01. 58. Schaich M, Harbich-Brutscher E, Pascheberg U, Mohr B, Soucek S, Ehninger G, et al. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica. 2002;87(5):455-64. Epub 2002/05/16. 59. Yang DH, Lee JJ, Mun YC, Shin HJ, Kim YK, Cho SH, et al. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. American journal of hematology. 2007;82(1):1-5. Epub 2006/09/21. 60. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature genetics. 2012;44(1):23-31. Epub 2011/12/06. 61. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(21):2889-96. Epub 2011/06/15. 62. Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119(2):559-68. Epub 2011/11/15. 63. Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood. 2011;118(10):2849-56. Epub 2011/07/19. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6522 | - |
dc.description.abstract | Roundabout 4 (Robo4) 是一種僅被發現存在於造血幹細胞及血管內皮細胞的膜蛋白。最近的研究發現造血幹細胞Robo4的表現與其在骨髓微環境中維持造血穩態有密切關係。
骨髓微環境(bone marrow microenvironment, niche)提供了造血幹細胞(hematopoietic stem cell, HSC) 進行自我更新 (self-renewal)、冬眠 (quiescence)、歸巢 (homing) 與植入(engraftment)、分化 (differentiation) 及增生的特殊環境。愈來愈多的研究顯示骨髓微環境可能與急性骨髓性白血病 (acute myeloid leukemia, AML) 的致病機轉 (leukemogenesis) 有關。 至今尚無針對Robo4是否表現於急性骨髓性白血病細胞的研究。因此為了解急性骨髓性白血病細胞Robo4表現的高低與急性骨髓性白血病患者臨床表現及預後、分子生物學特徵如細胞表面標記、染色體及非染色體基因異常等的關聯性,我們利用即時定量聚合酶連鎖反應合成法 (real-time quantitative polymerase chain reaction, RQ-PCR) 分析急性骨髓性白血病患者初診斷時骨髓 (bone marrow , BM) 檢體中Robo4 mRNA的表現。 骨髓檢體來自1995年至2006年間於台大醫院血液科診斷為急性骨髓性白血病且接受標準化學治療的病患共計148位,藉由即時定量聚合酶連鎖反應合成(RQ-PCR) 的方法分析初診斷時骨髓單核細胞Robo4 mRNA的表現。臨床表現分析包含性別、年齡、FAB分類、初診斷時的周邊白血球及芽細胞 (blast) 數目、血色素、血小板數目、LDH數值、染色體變化及預後影響的評估。分析Robo4 mRNA表現的高低與總體存活期 (overall survival)、無病存活期 (disease-free survival)、緩解率 (remission rate) 的相關性來評估其對預後的影響。 148位病患中有78位是男性、70位是女性,中位數年齡為46歲。研究結果發現急性骨髓性白血病患者初診斷時骨髓單核細胞Robo4 mRNA的表現都顯著高於正常對照組 (P=0.0016)。以0.010 (Robo4/RPLP0) 作為閥值 (cut-off value),患者分成Robo4高表現 (n=61) 與低表現 (n=87) 兩組。臨床表現方面,兩組的性別、年齡、初診斷時周邊白血球及芽細胞數目、血色素、血小板數目、LDH數值無顯著差。表面標記特徵方面,Robo4高表現病患的急性骨髓性白血病呈HLA-DR陽性(85.0% vs. 62.4%, P=0.003) 及CD56 陽性(30.0% vs. 8.4%, P=0.001) 的比例顯著較高。 142位 (96 %) 病患具初診段時有效的傳統染色體分析結果,其中67位 (47.2 %) 檢出同源性染色體異常。Robo4高表現的病患發生t(8;21) 的頻率(20% vs. 2.3%, P=0.0009) 顯著較高,t(15;17) 的頻率則顯著較低(1.6% vs. 14.9%, P=0.0081)。在染色體檢查無法驗出異常的基因變異方面,Robo4高表現的病患發生DNMT3A 突變的頻率 (P=0.0543) 顯著較高,CEBPAdouble mutation的頻率(P=0.024) 則顯著較低。 148位病患中有107位 (72.3%) 在接受標準治療後達到完全緩解 (complete remission, CR)。在病患的預後方面,Robo4高表現的病患有治療效果較差的傾向(CR rate, 63.9% vs.78.2%, P=0.0643)。在中位數為31個月的追蹤期內 (範圍介於1.0至160個月),Robo4高表現病患的總體存活期 (中位數, 17.0個月vs. 95.0個月, P =0.023) 及無病存活期 (中位數, 5.0個月vs. 15.0個月, P=0.024) 均顯著較差;分析其中99位中度風險染色體核型 (intermediate-risk cytogenetics) 的病患,Robo4高表現病患的總體存活期 (中位數, 13.5個月vs. 95.0個月, P =0.007) 及無病存活期 (中位數, 4.0個月vs. 10.0個月, P=0.025) 也顯著較差。 Cox proportional hazards 多變項分析可以發現,年齡大於50歲、初診斷時周邊白血球數目大於50,000/μL、預後不佳之染色體核型 (unfavorable cytogenetics) 及Robo4的高表現 (Hazard ratio 1.779, 95% CI 1.005-3.149, P=0.048)為總體存活期較差的獨立預後預測因子,CEBPAdouble mutation與NPM1mutation+/FLT3-ITDmutation- 則為總體存活期較佳的獨立預後預測因子;年齡大於50歲、初診斷周邊白血球數目大於50,000/μL、預後不佳之染色體核型(unfavorable cytogenetics) 及Robo4的高表現(Hazard ratio 1.779, 95% CI 1.005-3.149, P=0.048) 也是無病存活期較差的獨立預後預測因子,CEBPAdouble mutation與NPM1mutation+/FLT3-ITDmutation- 則也是無病存活期較佳的獨立預後預測因子。 本次研究的結果顯示急性骨髓性白血病患者初診斷時骨髓單核細胞Robo4 mRNA的高表現為預後不佳的象徵;總體存活期的預後預測在中度風險染色體核型的病患顯得更有意義。在白血病致病機轉 (leukemogenesis) 中,Robo4本身的作用機轉及其與t(8;21)、DNMT3A突變的交互作用值得進一步研究。 | zh_TW |
dc.description.abstract | Background and Purpose
Roundabout 4 (Robo4) is a transmembrane protein expressed specifically in endothelial cells and hematopoietic stem cells (HSCs). Recently, Robo4 expression was shown to be tightly associated with bone marrow (BM) microenvironment and involved in HSC homeostasis. BM microenvironment provides support for self-renewal, quiescence, homing, engraftment and proliferative potential for HSCs. Emerging evidence suggested that BM microenvironment may play a role in the leukemogenesis of acute myeloid leukemia (AML). Till now, there has been no study concerning the prognostic implication of Robo4 expression in de novo AML. Methods and Materials We investigated the RNA expression of genes encoding Robo4by real-time quantitative polymerase chain reaction in the BM from a cohort of 148 newly diagnosed de novo AML patients who received standard conventional chemotherapy and 20 healthy BM donors at the National Taiwan University Hospital. The expression of the target gene was normalized to that of the housekeeping gene RPLP0.The result was correlated with clinical features, cytogenetics, other genetic alterations and treatment outcomes. Results Among the 148 AML patients recruited, 78 were males and 70 were females with a median age of 46 years. Median levels of Robo4 expression were significantly higher in AML patients than in normal BM donors (P=0.0016). The patients were then divided into two groups, one with low expression of Robo4 (n=87) and the other with high expression (n=61), by using a cut-off point of 0.010 (Robo4/RPLP0). There was no difference in age, gender, hemogram and LDH levels between the patients with high and low Robo4 expression. Patients with high Robo4 expression had higher incidence of HLA-DR and CD56 expression on the leukemia cells (85.0% vs. 62.4%, P=0.003 and 30.0% vs. 8.4%, P=0.001, respectively). However, there was no difference in the expression of other antigens between the patients with high and low Robo4 expression. Chromosome data were available in 142(96%) patients at diagnosis and clonal chromosomal abnormalities were detected in 67 patients (47.2%). High Robo4 expression was closely association withchromosomal abnormalities t(8;21), but inversely correlated with t(15;17) (20% vs. 2.3%, P=0.0009 and 1.6% vs. 14.9%, P=0.0081, respectively). To investigate the interaction between Robo4expression and other genetic alterations in the pathogenesis of AML, a mutational screening of 16 other genes was also performed. We found that Robo4 expression was significantly higher in AML patients with DNMT3A mutation (P=0.0543), but lower in those with CEBPA mutation (P=0.0240). Among the 148 AML patients, 107 (72.3%) patients achieved a complete remission (CR) after standard intensive chemotherapy. High Robo4 expression was associated with a trend of inferior response (CR rate, 63.9% vs.78.2%, P=0.0643). With a median follow-up of 31 months (ranges, 1.0-160), patients with high Robo4 expression had significantly poorer overall survival (OS) and disease-free survival (DFS) than those with low Robo4 expression (median, 17.0 months vs. 95.0 months, P =0.023, and medium, 5.0 months vs. 15.0 months, P=0.024, respectively). In the subgroup of 99 patients with intermediate-risk cytogenetics, the differences between patients with high and low Robo4 expressionin OS (median, 13.5 months vs. 95.0 months, P= 0.007) and DFS (median, 4.0 months vs. 10.0 months, P=0.025) were still significant. In multivariate analysis, the independent poor risk factors for OS were older age > 50 years, high WBC count >50,000/μL, unfavorable karyotype, and high Robo4 expression (Hazard ratio 1.779, 95% CI 1.005-3.149, P=0.048). On the other hand, CEBPAdouble mutation and NPM1mutation+/FLT3-ITDmutation- were independent favorable prognostic factors. The independent poor risk factors for DFS included older age > 50 years, high WBC count >50,000/μL, unfavorable karyotype, and high Robo4 expression (Hazard ratio 1.600, 95% CI 1.026-2.495, P=0.038). CEBPAdouble mutation and NPM1mutation+/FLT3-ITDmutation- were also independent favourable factors for DFS. Conclusion Our results demonstrated that high pre-treatment expression of Robo4 in the BM indicates an unfavorable prognosis in de novo AML patients and the prognostic significance of Robo4 expression for OS in the subgroup of patients with intermediate-risk cytogenetics was even more obvious. Further studies are needed to explore the mechanisms of this gene expression and its interaction with t(8;21) and DNMT3A mutation in the leukemogenesis of AML. | en |
dc.description.provenance | Made available in DSpace on 2021-05-17T09:14:22Z (GMT). No. of bitstreams: 1 ntu-101-P98421020-1.pdf: 601870 bytes, checksum: 7332c8c6f5be32f8b94e74c5703e7d93 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 一、中文摘要(Chinese Abstract)---------------------------P2
二、緒論(Introduction)-----------------------------------P5 三、研究方法與材料(Methods and Materials)---------------P10 四、結果(Results)---------------------------------------P14 五、討論(Discussion)------------------------------------P16 六、展望(Perspective)-----------------------------------P18 七、英文簡述(English Summary)---------------------------P19 八、參考文獻 (References)-------------------------------P22 九、表(Tables)------------------------------------------P28 十、圖(Figure)------------------------------------------P33 | |
dc.language.iso | zh-TW | |
dc.title | Roundabout 4在原發性急性骨髓性白血病的研究 | zh_TW |
dc.title | Expression of Roundabout 4 in bone marrow mononuclear cells from de novo acute myeloid leukemia patients and its clinical significance | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林亮音,劉俊人,周文堅 | |
dc.subject.keyword | 急性骨髓性白血病,骨髓微環境,Robo 4, | zh_TW |
dc.subject.keyword | acute myeloid leukemia,microenvironment,Robo 4, | en |
dc.relation.page | 28 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2012-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf | 587.76 kB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。